Current Landscape of Immunotherapy in Breast CancerSylvia Adams, Elizabeth A. Mittendorf, Margaret E. Gatti‐Mays et al.|JAMA Oncology|2019Cited by 409
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic LeukemiaPatrick A. Brown, Mignon L. Loh, Lingyun Ji et al.|JAMA|2021Cited by 358
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip Pravin Patel, Razelle Kurzrock, Megan Othus et al.|Clinical Cancer Research|2020Cited by 326
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsMark R. Litzow, Martin S. Tallman, Zhuoxin Sun et al.|New England Journal of Medicine|2024Cited by 213
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful ActivityValsamo Anagnostou, Patrick M. Forde, Mark Yarchoan et al.|Clinical Cancer Research|2017Cited by 181